Virgin olive oil administration improves the effect of aspirin on retinal vascular pattern in experimental diabetes mellitus.
The aim of the present study is to evaluate the possible influence of virgin olive oil (VOO) on the effect of acetylsalicylic acid (ASA) in platelet aggregation, prostanoid and NO production and retinal vascular pattern in rats with experimental type 1-like diabetes. We used 100 male Wistar rats that were distributed into five groups: (1) non-diabetic rats (NDR); (2) untreated diabetic rats (DR); (3) DR treated with ASA (2 mg/kg per d per os (p.o.)); (4) DR treated with VOO (0.5 ml/kg per d p.o.); (5) DR treated with ASA plus VOO. The duration of diabetes was 3 months, and each treatment was administered from the first day of diabetes. Variables that were quantified were platelet aggregation (I(max)), thromboxane B(2) (TxB(2)), aortic prostacyclin (6-keto-PGF(1alpha)) and NO, and the percentage of retina with horseradish peroxidase-permeable vessels (HRP-PV). Diabetic rats showed a higher I(max) (35 %) and TxB(2) (63 %) than NDR, and a lower 6-keto-PGF(1alpha), NO and HRP-PV than NDR ( - 74.6 %). ASA and VOO administration reduced these differences and prevented the percentage of HRP-PV ( - 59.7 % with ASA and - 46.7 % with VOO). The administration of ASA plus VOO showed a strong platelet inhibition (80.2 v. 23.4 % for VOO and 50.6 % for ASA+VOO, P < 0.0001), and reduced HRP-PV differences to - 31.6 % (P < 0.001 with respect to DR and P < 0.0001 with respect to DR treated with ASA). In conclusion, the administration of VOO to rats with type 1-like diabetes mellitus improves the pharmacodynamic profile of ASA, and increases its retinal anti-ischaemic effect.
De La Cruz
Jose Pedro
JP
Laboratorio de Investigaciones Antitrombóticas e Isquemia Tisular (LIAIT), Department of Pharmacology and Therapeutics, School of Medicine, Campus de Teatinos s/n, 29071 Málaga, Spain.
Del Río
Sergio
S
López-Villodres
Juan Antonio
JA
Villalobos
Maria Auxiliadora
MA
Jebrouni
Nuria
N
González-Correa
Jose Antonio
JA
D000818:Animals; D001011:Aorta; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006735:Horseradish Peroxidase; D008297:Male; D009569:Nitric Oxide / Q000097:blood; D031658:Olea / Q000737:chemistry*; D000069463:Olive Oil; D010539:Permeability / Q000187:drug effects; D010938:Plant Oils / Q000494:pharmacology* / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012171:Retinal Vessels / Q000187:drug effects*; D013929:Thromboxane B2 / Q000097:blood
D000069463:Olive Oil; D010938:Plant Oils; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide; D013929:Thromboxane B2; D006735:Horseradish Peroxidase; D001241:Aspirin